Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05318833 Not yet recruiting - Clinical trials for Advanced Malignant Tumor

A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors

Start date: April 15, 2022
Phase: Phase 1
Study type: Interventional

This study is a multicenter, open phase I clinical study of dose escalation and dose extension of HRS7415 in subjects with advanced malignant tumors. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS7415 tablets.

NCT ID: NCT05318573 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.

NCT ID: NCT05317078 Active, not recruiting - Clinical trials for Epithelial Ovarian Cancer

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Start date: February 28, 2023
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to evaluate the safety and tolerability of AMG 794 in adult participants and to determine the optimal biological active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose.

NCT ID: NCT05316480 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Neoplasm

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.

NCT ID: NCT05316077 Recruiting - Oncology Clinical Trials

Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up

Start date: August 30, 2022
Phase:
Study type: Observational

This study is conducted within the frame of the Post-Market Surveillance (PMS) activities, as described in the Post Market Clinical Follow-up (PMCF) plan of Vectorio®. This study aims at collecting clinical data, to confirm the General Safety and Performance Requirements of Vectorio® which is a Lipiodol Resistant Mixing & Injection System for cTACE.

NCT ID: NCT05315700 Recruiting - Solid Tumors Clinical Trials

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Start date: March 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

NCT ID: NCT05315427 Completed - Advanced Cancer Clinical Trials

Impact of Music Therapy on Pain in Patients Treated for Advanced Cancer

MSPD
Start date: May 2, 2022
Phase:
Study type: Observational

The aim of this study is to assess the impact of music therapy on the pain of patients cared at the Montpellier Cancer Institute (ICM) for advanced cancer in a palliative situation and requiring full hospitalization or on an outpatient basis.

NCT ID: NCT05315180 Recruiting - Metastatic Cancer Clinical Trials

A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Start date: August 24, 2021
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

NCT ID: NCT05315167 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.

NCT ID: NCT05314803 Recruiting - Young Adult Cancer Clinical Trials

Yoga for Young Adults Affected by Cancer

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Yoga may enhance physical and psychological outcomes among young adults affected by cancer. Yet, yoga has rarely been studied in this population. We developed and piloted a yoga program, which is now ready for implementation and evaluation. This single-group, mixed-methods project will explore effectiveness and implementation of the yoga program.